Latest news with #DEA-compliant
Malaysian Reserve
08-05-2025
- Business
- Malaysian Reserve
Inmar Intelligence Expands MMCAP Relationship with New Medical Waste Management Contract
New contract brings secure drug take-back and sharps programs to over 34,500 MMCAP facilities, helping government-run providers meet compliance requirements, reduce risk, and protect community health WINSTON-SALEM, N.C., May 8, 2025 /PRNewswire/ — Inmar Intelligence, a leader in healthcare logistics and compliance solutions, today announced a new contract with MMCAP, a national cooperative purchasing organization that serves public-sector healthcare facilities. The agreement expands their long-standing relationship to include medical and pharmaceutical waste management services, giving members access to Inmar's full suite of secure drug disposal and sharps management programs. Across the country, public-sector healthcare organizations face growing pressure to manage pharmaceutical waste safely while navigating a complex mix of DEA, EPA, and state regulations. Many facilities, especially those with limited resources, struggle to implement secure disposal programs that prevent diversion, protect patients, and reduce environmental harm. The risks range from medication misuse to community exposure, and they are real and rising. Inmar's suite of waste management solutions offers a turnkey, cost-effective path to compliance. These services help reduce risk, simplify operations, and enable MMCAP members to take proactive steps in support of patient safety, environmental health, and responsible drug stewardship. With a proven track record and deep regulatory expertise, Inmar helps government-run and nonprofit facilities meet today's standards while preparing for tomorrow's oversight. The expanded contract introduces four key Inmar programs to MMCAP members: Consumer Drug Take-Back Receptacles (CDTB) – Secure, DEA-compliant receptacles for on-site disposal of unused or expired medications. MMCAP members, such as eligible public health clinics or correctional facilities, can install these units to support safe drug disposal for patients, reduce diversion risks, and meet regulatory expectations for community drug stewardship. Sponsored Consumer Drug Take-Back Receptacles (SCDTB) – A fully funded version of the CDTB program made possible through Inmar's manufacturer partnerships. Eligible MMCAP members in states with extended producer responsibility laws may qualify to receive and operate these drug take-back receptacles at no cost, expanding access to secure disposal without impacting budget. California Sharps (CA Sharps) Program – A compliant mail-back program that provides California-based members with safe, prepaid sharps disposal kits for community use. This helps MMCAP members meet California's specific sharps waste regulations while protecting patients and staff from needle-stick injuries and biohazard exposure. Inmar's ability to align national programs with state-level mandates helps MMCAP members avoid costly compliance gaps and expand access to essential services. In states with extended producer responsibility laws, including California, Illinois, Maine, Massachusetts, New York, Oregon, and Washington, eligible facilities may receive fully sponsored drug take-back solutions that lower costs and increase community impact. 'This agreement reflects our continued commitment to helping MMCAP members solve complex challenges with simple, scalable solutions,' said Brian Nightengale, President, Healthcare at Inmar Intelligence. 'From drug take-back to sharps disposal, our programs are designed to meet evolving regulatory needs while supporting safer, more sustainable communities. We're proud to serve as a trusted partner in helping government-run healthcare facilities strengthen both compliance and care delivery.' MMCAP is a national cooperative purchasing organization serving more than 34,500 government and nonprofit member facilities across all 50 states. The expansion of its agreement with Inmar comes at a critical moment, as regulatory scrutiny around pharmaceutical waste intensifies and healthcare organizations seek efficient, compliant solutions that improve both operational outcomes and community safety. For more information about Inmar Intelligence's healthcare waste solutions, visit About Inmar IntelligenceThrough data-driven technology and innovation, Inmar Intelligence optimizes the healthcare value chain, improving patient safety, access, and affordability. With over 40 years of experience partnering with health systems, pharmacies, and life sciences companies, Inmar delivers solutions that address the complex challenges of modern healthcare operations. Visit and follow us on LinkedIn. Contact us at solutions@ or call (866) 440-6917. Media Contact:Email: press@
Yahoo
04-05-2025
- Business
- Yahoo
DEA Diversion in Cannabis Chaos: MMJ Urges Terrance Cole, President Trump DEA Nominee to Dismantle Biden Era Cannabis Obstructors
Message to President Trump's Appointee: Terrance Cole Must Act on Cannabis Scientific Reform. "Mr. Cole has a historic opportunity to lead with integrity, science, and constitutional fidelity," said Boise. "He must put an end to this unlawful administrative hearing, root out DEA institutional marijuana bias, and restore lawful science-based regulatory practices." WASHINGTON, DC / / May 4, 2025 / MMJ BioPharma Cultivation announced it will file an emergency motion and lawsuit in the U.S. District Court for the District of Rhode Island following a controversial ruling by DEA Administrative Law Judge (ALJ) Teresa Wallbaum. Judge Wallbaum recently issued a ruling to vacate a previously granted stay-clearing the path for a DEA ALJ hearing before what MMJ asserts is a constitutionally defective tribunal. Judge Wallbaum retired immediately after issuing the ruling. The company's forthcoming legal action seeks to block the DEA's internal administrative hearing process, which MMJ argues violates the Supreme Court's landmark ruling in Axon Enterprise, Inc. v. FTC, and inflicts irreparable harm on its constitutional rights and medical mission. MMJ Direct Challenge to DEA Overreach The Axon decision, issued by the Supreme Court in 2023, affirmed that entities subject to unconstitutional agency proceedings can challenge them in federal court before being forced through the flawed administrative process. MMJ contends that the DEA's ALJ system, where judges are insulated from presidential oversight, runs afoul of Article II of the Constitution. "We are not just challenging DEA policy; we are defending the rule of law," said Duane Boise, CEO of MMJ BioPharma Cultivation. "The DEA cannot ignore Supreme Court precedent and funnel applicants into hearings that are constitutionally invalid." From Regulatory Delay to Constitutional Injury MMJ's application to grow pharmaceutical-grade marijuana for FDA-sanctioned clinical trials was filed in 2018. Since then, the company has: Built and passed inspection of a DEA-compliant facility Received a DEA Schedule I analytical registration Filed two FDA Investigational New Drug (IND) applications Been awarded FDA Orphan Drug Designation for Huntington's Disease Despite these milestones and the 60-day processing deadline set by the Medical Marijuana and Cannabidiol Research Expansion Act (MCREA), MMJ has waited over 2,300 days. "The damage done by these delays is not just procedural-it's personal," Boise added. "Patients living with Huntington's and MS deserve answers and access, not bureaucratic purgatory." Biden's Failed Cast of Characters: Milgram, Garland, Thomas Prevoznik, Matthew Strait For years, DEA Administrator Anne Milgram, Attorney General Merrick Garland, and the broader Biden administration have stood idle-overseeing a federal agency that continues to delay and deny legitimate medical cannabis research. Despite bipartisan legislation and judicial precedent, no meaningful reform has occurred. "The Biden administration had every opportunity to fix this. Instead, they turned a blind eye to patients and the Constitution," said Boise. Message to President Trump's Appointee: Terrance Cole Must Act Now, all eyes turn to Terrance Cole, President Trump's nominee for DEA Administrator, who MMJ urges to dismantle the obstructionist legacy left behind by the Biden-era leadership. "Mr. Cole has a historic opportunity to lead with integrity, science, and constitutional fidelity," said Boise. "He must put an end to this unlawful administrative hearing, root out DEA institutional bias, and restore lawful science-based regulatory practices." MMJ emphasized that Cole's leadership can mark a turning point: not just for the agency, but for tens of thousands of patients across the country. "This is about reclaiming the DEA from the grip of politics and putting patients first," Boise added. "Terrance Cole can either reform the agency-or risk continuing the shameful legacy of his predecessors." Federal Court Relief Sought MMJ's legal filing will request: A preliminary and permanent injunction halting the ALJ proceeding A declaration that the DEA's ALJ process violates the Constitution Expedited federal review in accordance with the Axon precedent "We are not seeking special treatment," Boise concluded. "We are demanding a fair, lawful process-something every American is entitled to. The DEA must be held accountable." MMJ is Represented by Attorney Megan Sheahan and Associates CONTACT:Madison Hiseymhisey@ SOURCE: MMJ International Holdings View the original press release on ACCESS Newswire
